These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 7865318

  • 1. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies.
    Temoshok LR.
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S277-80. PubMed ID: 7865318
    [No Abstract] [Full Text] [Related]

  • 2. Behavioral studies relevant to vaccine trial preparation: an introduction.
    Turner CF, Sheon AR.
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S273-6. PubMed ID: 7865317
    [Abstract] [Full Text] [Related]

  • 3. Preparations for AIDS vaccine trials. Recruitment and retention of in- and out-of-treatment injection drug users.
    Woody GE, Metzger D, Mulvaney F.
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S197-9. PubMed ID: 7865300
    [No Abstract] [Full Text] [Related]

  • 4. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection.
    MacQueen KM, Buchbinder S, Douglas JM, Judson FN, McKirnan DJ, Bartholow B.
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S261-4. PubMed ID: 7865314
    [No Abstract] [Full Text] [Related]

  • 5. Participation of homosexual/bisexual men in preventive HIV vaccine trials: baseline attitudes and concerns and predicted behaviors during trials.
    Douglas JM, Judson FN, Parks JP, Buchbinder S, McKirnan D.
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S257-60. PubMed ID: 7865313
    [No Abstract] [Full Text] [Related]

  • 6. Preparations for AIDS vaccine trials. Developing brief valid screening instruments for HIV-related sexual risk behavior among gay and bisexual men.
    McKirnan DJ, Doetsch J, Vanable P, Buchbinder S, Douglas JM, Judson F.
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S285-8. PubMed ID: 7865320
    [Abstract] [Full Text] [Related]

  • 7. Interest in HIV vaccines among injection drug users in Baltimore, Maryland.
    Vlahov D, Astemborski J, Solomon L, Galai N, Basarab L, Nelson KE.
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S265-8. PubMed ID: 7865315
    [Abstract] [Full Text] [Related]

  • 8. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
    Chesney MA, Lurie P, Coates TJ.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May 01; 9(1):30-5. PubMed ID: 7712232
    [No Abstract] [Full Text] [Related]

  • 9. Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors.
    Navaline HA, Snider EC, Petro CJ, Tobin D, Metzger D, Alterman AI, Woody GE.
    AIDS Res Hum Retroviruses; 1994 May 01; 10 Suppl 2():S281-3. PubMed ID: 7865319
    [Abstract] [Full Text] [Related]

  • 10. Overview: HIV vaccine feasibility studies.
    Sheon AR.
    AIDS Res Hum Retroviruses; 1994 May 01; 10 Suppl 2():S195-6. PubMed ID: 7865299
    [No Abstract] [Full Text] [Related]

  • 11. Feasibility and cohort development for HIV vaccine trials in Haiti.
    Deschamps MM, Johnson WD, Pape JW.
    AIDS Res Hum Retroviruses; 1994 May 01; 10 Suppl 2():S231-3. PubMed ID: 7865308
    [Abstract] [Full Text] [Related]

  • 12. Social and behavioral issues in phase III HIV preventive vaccine trials.
    Grinstead OA.
    AIDS; 1995 May 01; 9 Suppl A():S245-50. PubMed ID: 8819592
    [No Abstract] [Full Text] [Related]

  • 13. Will preventive HIV vaccine efficacy trials be possible with female injection drug users?
    Meyers K, Metzger DS, McLellan AT, Navaline H, Sheon AR, Woody GE.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec 15; 10(5):577-85. PubMed ID: 8548338
    [Abstract] [Full Text] [Related]

  • 14. HIV preventive vaccine efficacy trials in the United States: an overview of target communities' concerns.
    Hodel D.
    AIDS Res Hum Retroviruses; 1994 Dec 15; 10 Suppl 2():S255-6. PubMed ID: 7865312
    [No Abstract] [Full Text] [Related]

  • 15. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US.
    Priddy FH, Cheng AC, Salazar LF, Frew PM.
    Int J STD AIDS; 2006 Feb 15; 17(2):99-102. PubMed ID: 16464270
    [Abstract] [Full Text] [Related]

  • 16. Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.
    Slack CM.
    Am J Bioeth; 2011 Jun 15; 11(6):21-2. PubMed ID: 21678209
    [No Abstract] [Full Text] [Related]

  • 17. Response to Open Peer Commentaries on "Relative versus absolute standards for everyday risk in adolescent HIV prevention trials: expanding the debate".
    Snyder J, Miller CL, Gray G.
    Am J Bioeth; 2011 Jun 15; 11(6):W1-3. PubMed ID: 21678202
    [No Abstract] [Full Text] [Related]

  • 18. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein.
    Luzi AM, Gallo P, Colucci A, Marcotullio S, Bellino S, Longo O, Ensoli B.
    AIDS Care; 2011 Aug 15; 23(8):939-46. PubMed ID: 21390884
    [Abstract] [Full Text] [Related]

  • 19. Lack of volunteers for vaccine.
    AIDS Patient Care STDS; 1999 Sep 15; 13(9):572. PubMed ID: 10813047
    [No Abstract] [Full Text] [Related]

  • 20. Interest in HIV vaccines among Italian injection drug users. The Network Interregionale SERT.
    Serpelloni G, Vlahov D, Mazzi M, Rezza G.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct 01; 10(2):206-7. PubMed ID: 7552488
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.